Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor Microenvironment Remodeling
Pharmaceutics · 29.07.2026 · 18 (8) · 934
DOI: 10.3390/pharmaceutics18080934 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 29.07.2026. Verfasst von Jun Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Soongsil University, Seoul 06978, Republic of Korea. Die Arbeit nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Soongsil University, Ministry of Education.
Abstract (Originalsprache)
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies because of aggressive tumor biology, pervasive therapeutic resistance, rapid adaptive reprogramming, and a profoundly immunosuppressive tumor microenvironment. This review summarizes recent advances in KRAS-targeted therapies, DNA damage response (DDR)-directed strategies, immune-redirection platforms, and tumor microenvironment modulation.
Methods
We conducted a narrative review of peer-reviewed publications, clinical trial reports, trial registries, and selected conference data addressing emerging therapeutic strategies for PDAC.
Results
KRAS-targeted therapies, including KRAS G12D-selective and multi-selective RAS(ON) inhibitors, have demonstrated substantial preclinical and emerging clinical activity while revealing diverse mechanisms of adaptive resistance. DDR-directed approaches are expanding beyond BRCA-mutated disease toward functional homologous recombination deficiency, replication stress, and synthetic lethality. In parallel, bispecific antibodies, T-cell engagers, and CAR-T-cell therapies have generated preliminary evidence of antitumor activity, although stromal exclusion, antigen heterogeneity, and immune suppression remain major barriers. These advances indicate that therapeutic resistance in PDAC is a dynamic process involving interconnected oncogenic, genomic, stromal, metabolic, and immune mechanisms.
Conclusions
Future progress will require biologically informed treatment frameworks integrating complementary therapeutic modalities according to baseline tumor biology and treatment-induced adaptive states, supported by longitudinal biomarkers and rational clinical trial design.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, Soongsil University, Seoul 06978, Republic of Korea.
- AI-Bio Convergence Research Institute, Soongsil University, Seoul 06978, Republic of Korea.
ORCID-Profile: Jun Kim
Förderung
- Soongsil University
- Ministry of Education
Zitieren
APA
Kim, J., & Kang, S. (2026). Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor Microenvironment Remodeling. Pharmaceutics, 18(8), 934. https://doi.org/10.3390/pharmaceutics18080934
Vancouver
Kim J, Kang S. Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor Microenvironment Remodeling. Pharmaceutics. 2026;18(8):934. doi:10.3390/pharmaceutics18080934
BibTeX
@article{Kim2026,
author = {Kim, Jun and Kang, Seounghun},
title = {Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor Microenvironment Remodeling},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {8},
pages = {934},
doi = {10.3390/pharmaceutics18080934}
}
EUVIMED